long term side effects of glp-1 receptor agonists Overdose risks increase as demand for injectable weight-loss drugs on the rise, research finds New study: “GLP-1 Receptor Agonists
Description
Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ
The investigators increased the pemvidutide dose gradually over the first 4 weeks to reach the 2.4-mg dose
However, no significant differences were observed for birth length, large or small for gestational age outcomes, or cesarean delivery rates
This may be partly mediated by improvements in weight loss and glucose control
The Precision Peptide Genetic Test ($99 add-on or $298 standalone) evaluates genetic variants in GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313revealing predispositions in peptide genetic pathways that predict individual medication response
44 There are ongoing studies evaluating the efficacy of orforglipron on weight loss and cardiovascular outcomes (clinical trial number NCT05803421
